Stem Cells
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

First published online February 2, 2006
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2005-0577v1
24/5/1407    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dimarakis, I.
Right arrow Articles by Levicar, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dimarakis, I.
Right arrow Articles by Levicar, N.
Submitted on November 22, 2005
Accepted on January 18, 2006

Letter to the Editor

Cell culture medium composition and translational adult bone marrow-derived stem cell research

Ioannis Dimarakis 1* and Natasa Levicar 1

1 Division of Surgery, Oncology, Reproductive Biology and Anaesthetics, Imperial College London, Hammersmith Hospital Campus, London, United Kingdom

* To whom correspondence should be addressed. E-mail: id502{at}ic.ac.uk.


  Abstract

The growing body of adult bone marrow-derived stem cell research in regenerative medicine has recently entered the clinical transplantation setting. The need for a robust flow of data from basic to translational scientists is imperative. All animal and/or human derived products should ideally be excluded and synthetic recombinant alternatives utilised instead. A variety of reasons make such an approach favorable including achievement of sounder control levels, reduction of any prion, viral or zoonose contamination risk, avoidance of possible immunological reactions as well as decrease in demand on animal supplies. At a preclinical level, investigative cell culture protocols must incorporate serum-free media groups alongside control conditions. Finally, autologous serum should not be neglected until an "off-the-shelf" alternative becomes available in the future.




This article has been cited by other articles:


Home page
 Stem CellsHome page
F. Mannello and G. A. Tonti
Concise Review: No Breakthroughs for Human Mesenchymal and Embryonic Stem Cell Culture: Conditioned Medium, Feeder Layer, or Feeder-Free; Medium with Fetal Calf Serum, Human Serum, or Enriched Plasma; Serum-Free, Serum Replacement Nonconditioned Medium, or Ad Hoc Formula? All That Glitters Is Not Gold!
Stem Cells, July 1, 2007; 25(7): 1603 - 1609.
[Abstract] [Full Text] [PDF]

Home page
 Stem CellsHome page
A. Kocaoemer, S. Kern, H. Kluter, and K. Bieback
Human AB Serum and Thrombin-Activated Platelet-Rich Plasma Are Suitable Alternatives to Fetal Calf Serum for the Expansion of Mesenchymal Stem Cells from Adipose Tissue
Stem Cells, May 1, 2007; 25(5): 1270 - 1278.
[Abstract] [Full Text] [PDF]

Home page
 Stem CellsHome page
M. G. Berger, R. Veyrat-Masson, C. Rapatel, S. Descamps, J. Chassagne, and N. Boiret-Dupre
Cell Culture Medium Composition and Translational Adult Bone Marrow-Derived Stem Cell Research
Stem Cells, December 1, 2006; 24(12): 2888 - 2890.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
STEM CELLS THE ONCOLOGIST CME ALPHAMED PRESS JOURNALS

Copyright © 2006 by AlphaMed Press.